09.21.2021 - Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Additional data show a booster increases protection 94 percent protection in the U.S. with booster given at two monthsFour-fold increase in antibodies when given at two months 12-...
09.19.2021 - New Data on RYBREVANT® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
CHRYSALIS-2 findings presented at ESMO Annual Congress 2021 suggest that RYBREVANT® and lazertinib combination has encouraging anti-tumor activity in this population that has...
09.19.2021 - RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
New analysis from CHRYSALIS study presented at the ESMO Annual Congress 2021 supports simultaneously targeting the extracellular and catalytic domains of EGFR
Supplier Quality Expectations
In order to be considered as a potential supplier or to continue supplying Companies within the Johnson & Johnson Family of Companies, suppliers must meet a set of minimum expectations.